Eastern equine encephalitis (EEE) is a viral disease that is transmitted primarily through mosquitoes. As such, it tends to pose overwhelming public health concern in places where these vectors exist in higher numbers. Our company is dedicated to driving progress in the development of impactful vaccines and therapies tailored for Eastern equine encephalitis, aiming to address the urgent health challenges posed by this disease.
Introduction to Eastern Equine Encephalitis
Eastern equine encephalitis (EEE) is a serious viral disease caused by Eastern equine encephalitis virus (EEEV), which is an arbovirus that belongs to the Togaviridae family genus Alphavirus . In The United States, the EEEV is endemic to the Atlantic and Gulf Coast regions where The wetland is well supplied and because of that gets mainly disseminated by mosquito bites. The clinical picture of this disease is very broad, starting from low-grade fever, all the way to neurological disorders such as encephalitis, and it can be debilitating and fatal. The mortality rate in case of EEE can be as high as 30% and those that survive, are left with dire neurological effects.
Fig.1 Vaccine strategies against encephalitic Alphavirus infections. (Stromberg Z. R., et al., 2020)
Vaccine Development for Eastern Equine Encephalitis
Live Attenuated Vaccines
Although the live attenuated vaccines developed for horses show promise in the veterinary sphere, the trend remains questionable for human beings. Immunization of this nature doesn't pose a risk when the recipient has a healthy immune system. However, significant safety concerns arise when the vaccine is administered to an immunocompromised individual as the downside far outweighs the benefits.
Inactivated Vaccines
The inactivated PE-6 strain EEEV vaccine (TSI-GSD 104) is the foremost contender in the market for EEEV vaccination. Studies have proven that it has a high immunogenic value and that a three-given schedule where the dosing occurs on day 0, 7, and 28 has an 84% seroconversion rate, far greater than the 54% seen with shorter schedules.
Therapeutics Development for Eastern Equine Encephalitis
Immunomodulatory Therapies
Therapeutics for EEE include immunomodulatory therapies like intravenous immunoglobulin and corticosteroids that aim to dampen the host's immune system and inflammation to limit morphological damage. There are indications indicating that IVIG may turn out to be extremely beneficial in grave cases of EEE.
Since the occurrence of seizures in cases of EEE is greatly pronounced, administration of anticonvulsant medications forms a major part of therapeutic. These medications curtail further seizure activity thus minimizing the extent of further neurological impairment. The type of anticonvulsant and the period of therapy depend on the clinical condition of the patient and the degree of the neurological involvement.
Our Services
Our firm, as a premier company, engages in the full-fledged support for the EEE vaccine and therapy development projects. Understanding the disease on a pathophysiological level allows us to engage in high end scientific research. Our goal is to aadhere to solving the pressing concerns posed by the EEE on the market.
Preclinical Research
- Pharmacodynamics Study Services
- Pharmacokinetics Study Services
- Drug Safety Evaluation Services
Disease Models
- Golden Hamster (Mesocricetus auratus) Models
- Mouse (BALB/c, C57BL/6, NIH Swiss, and CD-1) Infection Models
- Guinea Pig (Hartley strain) Models
- Non-human Primate Models
Infection route: intranasal, subcutaneous, and aerosol exposure
Preclinical research is a critical phase in the development of any new vaccine or therapy. Our services include the design and execution of preclinical studies, which involve rigorous testing in controlled laboratory settings. If you are interested in our services, please feel free to contact us.
References
- Stromberg, Zachary R., et al. "Vaccine advances against Venezuelan, eastern, and western equine encephalitis viruses." Vaccines 8.2 (2020): 273.
- Pierson, Benjamin C., et al. "Safety and immunogenicity of an inactivated eastern equine encephalitis virus vaccine." Vaccine 39.20 (2021): 2780-2790.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
